Eric Rosenfeld
Co-Founder & Partner @ Oregon Venture Fund
Portland, United States
Eric Rosenfeld is a Series A investor at Oregon Venture Fund in Portland focused on Biopharma and Life Science. Eric Rosenfeld - Founder: Eric launched the Oregon Angel Fund with Bob Ward in 2007 to combine the collective wisdom and horsepower of a select group of active, accomplished angel investors with the rigor and discipline of a venture fund. OAF has since grown to become the most active local venue for funding startups in terms of both participantsand dollars invested - OAF and its 200+ investors have placed over $50M with 45 local startups that now employ over 2,100 people. Previously, Eric co-founded Capybara Ventures, was a principal owner of Second Story Interactive Studios, and director of corporate business development for Mentor Graphics. Eric also worked as a technology and industry analyst for SRI International and was a research fellow at the Stanford Graduate School of Business. In addition to serving on several portfolio company boards, Eric is board chair of the Catlin Gabel School, and past chair of the Oregon Entrepreneurs Network, Angel Oregon, and the Oregon Jewish Community Foundation. Eric received his MBA from The Institute for Management Development (IMD) in Lausanne, Switzerland, and degrees in Industrial Engineering and American Studies from Stanford University.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Eric Rosenfeld invests in
Stages Eric Rosenfeld invests in
Countries Eric Rosenfeld invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biopharma 1 (25%)
- Life Science 1 (25%)
- Biotechnology 1 (25%)
- Food Processing 1 (25%)
- Food and Beverage 1 (25%)
Stage
- Series A 1 (25%)
- Series C 1 (25%)
- Series D 1 (25%)
- Funding Round 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process.Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com. | $10.4M / Series D / Jan 14, 2020 | ||
| Salt and Straw is an ice cream company that produces and offers ice cream made by hand w/ local ingredients. The company was launched in 2011 by cousins Kim and Tyler Malek. | $4.5M / May 22, 2019 | ||
| Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process.Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com. | $12M / Series C / May 30, 2018 | ||
| Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process.Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com. | $5.1M / Series A / Feb 02, 2016 |
Co-Investors
About Oregon Venture Fund
Founded in 2007, the Oregon Venture Fund is the largest and most active venture fund focused on supporting startups and growth companies with a presence in Oregon and SW Washington. The fund has invested over $199 million and is backed by the leaders of Oregon’s business, technology, and entrepreneurial communities. Consistently one of the top performing venture funds in North America, OVF invests $15 million annually in the most promising startups and growth companies in Oregon and SW Washington. Over 7,080 jobs have been created by the 88 companies in the portfolio. OVF’s largest investors include the State of Oregon, Oregon Community Foundation, and Meyer Memorial Trust. OVF invests $500K to $4M per round and can allocate up to $10M for each portfolio company. The fund is stage and sector agnostic.
Oregon Venture Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ann Carney Nelson
Member of Investment Strategy Board
|
|||
|
Eric Rosenfeld
Co-Founder & Partner
|
|||
Lynn Fletcher
Operations & Investor Relations
|
|||
Scott Sandler
Investor
|
|||
Alline Akintore
principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Eric Rosenfeld invest in?
Eric Rosenfeld invests primarily in Biopharma, Life Science and Biotechnology startups, most often at Series A and Series C stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Eric Rosenfeld?
Public channels for Eric Rosenfeld include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Eric Rosenfeld last invest?
The most recent investment recorded for Eric Rosenfeld closed in Jan 2020. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
